Abstract
Retrocyclins are synthetic θdefensins that were reconstructed from genetic blueprints that had remained unused for at least 7.5 million years. From phylogenetic studies, it appears that θdefensins arose in Old World Monkeys, after that lineage had separated from the prosimians and New World Monkeys. Although some nonhuman primates continue to produce θdefensin peptides today, Homo sapiens and his gorilla, bonobo, and chimpanzee relatives do not. Their inability to do so reflects the common inheritance of defective θdefensin genes which contain a premature stop codon that aborts translation. We can only speculate if this ancient genetic event has any contemporary relevance. However, it is noteworthy that synthetic retrocyclins can prevent the entry of HIV-1 and other viruses (e.g., HSV-2) into otherwise susceptible human target cells. Our studies suggest that their antiviral properties are intimately linked to an ability to bind carbohydrate epitopes displayed by viral and cell-surface glycoproteins involved in viral entry. The ability of retrocyclins to recognize and bind carbohydrate and glycan moieties is shared by θdefensins (RTDs) from rhesus monkeys and by several - but not all - human αdefensins. In addition to being the only cyclic peptides of animal origin, the lectin-like activity of θdefensins gives them the added distinction of being the smallest sugar-binding molecules of natural origin identified to date. This unusual combination makes θdefensins intriguing molecular prototypes that could be used to design novel carbohydrate-binding or antiviral agents.
Keywords: antiviral, cyclic peptides, hiv-1 uptake inhibitors, lectin, retrocyclin, theta-defensin
Current Protein & Peptide Science
Title: Retrocyclins: Using Past as Prologue
Volume: 5 Issue: 5
Author(s): Alexander M. Cole, Wei Wang, Alan J. Waring and Robert I. Lehrer
Affiliation:
Keywords: antiviral, cyclic peptides, hiv-1 uptake inhibitors, lectin, retrocyclin, theta-defensin
Abstract: Retrocyclins are synthetic θdefensins that were reconstructed from genetic blueprints that had remained unused for at least 7.5 million years. From phylogenetic studies, it appears that θdefensins arose in Old World Monkeys, after that lineage had separated from the prosimians and New World Monkeys. Although some nonhuman primates continue to produce θdefensin peptides today, Homo sapiens and his gorilla, bonobo, and chimpanzee relatives do not. Their inability to do so reflects the common inheritance of defective θdefensin genes which contain a premature stop codon that aborts translation. We can only speculate if this ancient genetic event has any contemporary relevance. However, it is noteworthy that synthetic retrocyclins can prevent the entry of HIV-1 and other viruses (e.g., HSV-2) into otherwise susceptible human target cells. Our studies suggest that their antiviral properties are intimately linked to an ability to bind carbohydrate epitopes displayed by viral and cell-surface glycoproteins involved in viral entry. The ability of retrocyclins to recognize and bind carbohydrate and glycan moieties is shared by θdefensins (RTDs) from rhesus monkeys and by several - but not all - human αdefensins. In addition to being the only cyclic peptides of animal origin, the lectin-like activity of θdefensins gives them the added distinction of being the smallest sugar-binding molecules of natural origin identified to date. This unusual combination makes θdefensins intriguing molecular prototypes that could be used to design novel carbohydrate-binding or antiviral agents.
Export Options
About this article
Cite this article as:
Cole M. Alexander, Wang Wei, Waring J. Alan and Lehrer I. Robert, Retrocyclins: Using Past as Prologue, Current Protein & Peptide Science 2004; 5 (5) . https://dx.doi.org/10.2174/1389203043379657
DOI https://dx.doi.org/10.2174/1389203043379657 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
Call for Papers in Thematic Issues
Advancements in Proteomic and Peptidomic Approaches in Cancer Immunotherapy: Unveiling the Immune Microenvironment
The scope of this thematic issue centers on the integration of proteomic and peptidomic technologies into the field of cancer immunotherapy, with a particular emphasis on exploring the tumor immune microenvironment. This issue aims to gather contributions that illustrate the application of these advanced methodologies in unveiling the complex interplay ...read more
Artificial Intelligence for Protein Research
Protein research, essential for understanding biological processes and creating therapeutics, faces challenges due to the intricate nature of protein structures and functions. Traditional methods are limited in exploring the vast protein sequence space efficiently. Artificial intelligence (AI) and machine learning (ML) offer promising solutions by improving predictions and speeding up ...read more
Nutrition and Metabolism in Musculoskeletal Diseases
The musculoskeletal system consists mainly of cartilage, bone, muscles, tendons, connective tissue and ligaments. Balanced metabolism is of vital importance for the homeostasis of the musculoskeletal system. A series of musculoskeletal diseases (for example, sarcopenia, osteoporosis) are resulted from the dysregulated metabolism of the musculoskeletal system. Furthermore, metabolic diseases (such ...read more
Protein Folding, Aggregation and Liquid-Liquid Phase Separation
Protein folding, misfolding and aggregation remain one of the main problems of interdisciplinary science not only because many questions are still open, but also because they are important from the point of view of practical application. Protein aggregation and formation of fibrillar structures, for example, is a hallmark of a ...read more
Related Journals
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Molecular Markers of Angiogenesis and Metastasis in Lines of Oral Carcinoma after Treatment with Melatonin
Anti-Cancer Agents in Medicinal Chemistry Natural Proteinaceous Inhibitors of Serine Proteases
Current Pharmaceutical Design Infringement of the Barriers of Cancer Via Dietary Phytoconstituents Capsaicin Through Novel Drug Delivery System
Current Drug Delivery The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets Personalized Nanoparticles for Cancer Therapy: A Call for Greater Precision
Anti-Cancer Agents in Medicinal Chemistry The Functional Role of Oncogenic LncRNA BCAR4 for Cancer Outcome
Current Pharmaceutical Design Imaging of Spinal Bone Tumors: Principles and Practice
Current Medical Imaging MicroRNAs Implications in the Onset, Diagnosis, and Prognosis of Osteosarcoma
Current Molecular Medicine Diabetic Bone Fracture Repair: A Progenitor Cell-Based Paradigm
Current Stem Cell Research & Therapy Recent Advances in Enone and NO-Releasing Derivatives of Oleanolic Acid with Anti-cancer Activity
Mini-Reviews in Organic Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Advancements in the Treatment and Repair of Tendon Injuries
Current Tissue Engineering (Discontinued) Metallic Nanoparticles as SERS Agents for Biomolecular Imaging
Current Pharmaceutical Biotechnology The Mitochondrial Thioredoxin is Required for Liver Development in Zebrafish
Current Molecular Medicine Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity
Current Medicinal Chemistry Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets Sex Hormones and their Analogues in Neuroimmune Biology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology